다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Viracta Therapeutics Inc (VIRX)
Viracta Therapeutics Inc (VIRX) 뉴스

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:VIRX

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/18	05:05	GlobeNewswire Inc.	Viracta Therapeutics Announces New Employment Inducement Grants	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/17	05:26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/17	05:23	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/15	05:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/14	20:00	GlobeNewswire Inc.	Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/10	06:04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/10	05:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/10	05:05	GlobeNewswire Inc.	Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/05/08	05:05	GlobeNewswire Inc.	Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/04/15	21:00	GlobeNewswire Inc.	Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/04/01	21:30	GlobeNewswire Inc.	Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/03/08	07:04	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/03/08	06:19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/03/08	06:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/03/08	06:05	GlobeNewswire Inc.	Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/29	22:00	GlobeNewswire Inc.	Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/28	10:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/28	09:56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/28	09:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/14	11:04	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/02/07	06:05	GlobeNewswire Inc.	Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:VIRX	Viracta Therapeutics Inc
2024/01/04	22:00	GlobeNewswire Inc.	Viracta Therapeutics Provides Clinical Update and Outlook for 2024	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/12/12	22:00	GlobeNewswire Inc.	Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/12/05	06:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/12/04	22:30	GlobeNewswire Inc.	Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/11/29	09:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/11/29	09:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/11/18	07:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/11/10	06:32	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIRX	Viracta Therapeutics Inc
2023/11/09	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIRX	Viracta Therapeutics Inc

검색 관련기사 보기:NASDAQ:VIRX

1 2 3 4 5 6 7 다음 >>

OMX Iceland Small Cap GI

Anglo Am.4.875a

OMX Helsinki Automobiles...

Vontobel Financial Produ...

BNPP HYSRI INAV

Resolute Mining

BlockMason Credit Protocol

Mace Security (QB)

NationaleNederlanden Ban...

Chiba Bank (PK)

Vontobel Financial Produ...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관